Inflammation and poor response to treatment with erythropoietin in chronic kidney disease Authors

Chronic kidney disease (CKD) is a serious public health problem and its incidence has increased in recent years. It is progressive and is associated with high morbidity and mortality rates.1 There are several conditions associated with CKD onset and progression. We stress the following: obesity, hypertension and diabetes mellitus. In addition to these conditions, there are signs of inflammation in the pathophysiology of CKD.1 This disease can cause numerous complications: cardiovascular disease (CVD) and anemia are the most prevalent and DOI: 10.5935/0101-2800.20150039 The prevalence of kidney chronic disease (CKD) has increased in recent years and several risk factors have been associated with the onset and progression of CDK, such as obesity, hypertension and diabetes mellitus. In addition, anemia is one of the complications of CRD, mainly by iron and erythropoietin (EPO) deficiency and the management of this situation is with exogenous erythropoietin, but patients undergoing dialysis present chronic inflammatory process followed by EPO resistance and anemia, malnutrition, worse of atherosclerosis and increased mortality ratio. The aim of this study was to review the association of erythropoietin resistance and chronic inflammatory process in patients with chronic renal disease. AbstrAct